Latest "Medicare Diabetes Screening Project" News Stories

02:12 EST 15th November 2018 | BioPortfolio

Here are the most relevant search results for "Medicare Diabetes Screening Project" found in our extensive news archives from over 250 global news sources.

More Information about Medicare Diabetes Screening Project on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Medicare Diabetes Screening Project for you to read. Along with our medical data and news we also list Medicare Diabetes Screening Project Clinical Trials, which are updated daily. BioPortfolio also has a large database of Medicare Diabetes Screening Project Companies for you to search.

Showing "Medicare Diabetes Screening Project" News Articles 1–25 of 10,000+

Thursday 15th November 2018

Mobidiag Receives Final €4M Tranche of €15M EIB Financing

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for inno...

Puretech Health plc PRTC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryPuretech Health plc Puretech, formerly PureTech Ventures LLC is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company offers human proof of concept and pivotal stage programs. It develops a microbiome immune system drugdiscovery platform and drug candidates for immunemediated diseases; and pr...

YITU Raises $15 Million for AI-Supported Cancer Diagnosis

YITU Healthcare, a subsidiary of Shanghai artificial intelligence company YITU, raised nearly $15 million to apply AI to early cancer detection and screening. The company aims to develop a "map of preventing cancer with AI." It will spend the money over five years to develop new products. It already has an AI-aided CT-scan reader to diagnose lung cancer and create a big data library. The pr...

Wednesday 14th November 2018

Stemina Biomarker Discovery Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryStemina Biomarker Discovery Inc Stemina is a metabolomics company that discovers, develops, and commercializes molecular biomarkers to improve drug safety and human health. The company builds human cellular models for toxicity screening of drug candidates, chemical compounds, cosmetic and tobacco ingredients. It offers devTOX, a biomarkerbased human invitro assay for prediction of developme...

Receiver of 19 Skyline South Dakota Skilled Nursing Facilities Proposes Plan to Close Two Facilities

The Court appointed Receiver for 19 skilled nursing facilities that were operated by Skyline Healthcare and its affiliates in South Dakota, Black Hills Receiver LLC, today announced that it has determined that it is in the best interest of the residents, under the circumstances, to carefully plan for and pursue closure of two skilled nursing facilities. Af...

Exclusive: Digital health company Heartflow gets Japanese reimbursement approval for cardiac diagnostic tech

The new Japanese reimbursement policy will go into effect on Dec. 1 and follows positive coverage decisions by Medicare and the United Kingdom’s National Health Services.

SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation

Patients with type 2 diabetes treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have a higher risk of lower limb amputation and diabetic ketoacidosis than those who take glucagon-like...

Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results for the quarter ended September 30, 2018. As of September 30, 2018, the Company reported $13.8 million in cash, compared to $6.2 million as of December 31, 2017. ...

Opioid Prescribing Guidelines Will Be More Template Than Commandment

Commissioner Gottlieb says US FDA does not intend to force physicians to adhere to opioid prescribing guidelines being developed by...   

Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock

Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital...    

SGLT2 Inhibitors Tied to Increased Risk for Amputation, Diabetic Ketoacidosis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with twice the risk for lower limb amputation and diabetic ketoacidosis relative to comparator diabetes drugs, an...

SunLink Health Systems, Inc. Announces Fiscal 2019 First Quarter Results

SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $817,000 (a loss of $0.11 per fully diluted share) for its first fiscal quarter ended September 30, 2018 compared to a loss of $224,000, (a loss of $0.02 per fully diluted share) for the quarter ended September 30, 2017. Net loss for the quarter ended Sep...

Where Medicare Advantage will cost the least in 2019

Healthcare costs around the country vary across settings and services, and the same is true for Medicare Advantage, which is expected to grow to 22.6 million members in 2019.

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection

Data Shows Significant Improvement in Clinically Relevant Endpoints SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc ...

MANIC PANIC Introduces Dye for Peace

Giving over 15% of profits to charity annually, the brand introduces new effort. NEW YORK (PRWEB) November 14, 2018 While known the world over for revolutionizing hair color, MANIC PANIC® founders Tish and Snooky have enthusiastically been at the forefront of animal rights and rescue since their childhood. Shortly after establishing the brand in 1977, Tish and Snooky began actively contribut...

Helping an Oral Diabetes Drug Go the Extra Mile

NewsStephen Buckley and colleagues have reformulated a prospective therapy for type 2 diabetes (T2D) now under clinical investigation as an oral treatment. Contrib

Vivus Inc VVUS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryVivus Inc Vivus is a biopharmaceutical company which develops and commercializes nextgeneration therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia phentermine and topiramate extendedrelease, indicated for the chronic weight management in adult patients; and Stendra/Spedra avanafil, an oral phosphodiest...

Humana Inc HUM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryHumana Inc Humana is a health and wellbeing company that offers health insurance and Medicare plans, insurance products, and health and wellness services to healthcare providers, employers, individuals, administrators, government, and the public sector. The company's Medicare products and services include Medicare Advantage plan, prescription drug plan, Medicare supplement insurance plans, ...

SGLT2 Inhibitor Amputation Risk Seen in Real-World Diabetes Study

The risk of lower limb amputations and diabetic ketoacidosis associated with use of SGLT2 inhibitors for type 2 diabetes are notable but small, the Scandinavian authors note. Medscape Medical News

HemaCare Provides Starting Material for Three FDA Approved Cellular Therapies

40-Years of Blood Collection and Processing Proudly Supporting the Development of Life-Changing Medicines HemaCare Corporation (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces their involvement as a provider of

Humana Medicare Advantage Plan Addresses High Fall Rates Among Older Adults in St. Louis

MA Plan influenced by Washington University research through the Home Hazard Removal Program (HARP) that addresses home hazards for aging St. Louisans Humana Inc. (NYSE: HUM) is offering a Medicare Advantage plan in St. Louis with a fall prevention benefit. The benefit is administered by Washington University in conjunction with

MannKind Corp MNKD Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryMannKind Corp MannKind is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapidaction inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation...

Size Doesn't Matter - Quality of Video Ads More Important Than Budget

CAMBRIDGE, Mass., Nov. 14, 2018 /PRNewswire/ -- Wistia has announced the results for its unique One Ten One Hundred research project where with Sandwich video, Read more...

Women With Diabetes Can Control Vaginal Health, According to Mache Seibel, M.D.

With approximately 9.7 million women in the U.S. suffering with diabetes and almost 50 million U.S. adults with prediabetes, most of the women are experiencing uncomfortable vaginal symptoms like recurrent yeast and bacterial infections, vaginal dryness, reduced sexual interest, and painful intercourse that can adversely affect quality of life. ...

Clinical Challenges: Heart Failure Protection in Diabetes Drugs

(MedPage Today) -- What is the link between HF, diabetes?

Quick Search


News Quicklinks